Nature Reviews Clinical Oncology

ISSN: 1759-4774

Journal Home

Journal Guideline

Nature Reviews Clinical Oncology Q1 Unclaimed

Nature Publishing Group United Kingdom
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Nature Reviews Clinical Oncology is a journal indexed in SJR in Oncology with an H index of 155. It has an SJR impact factor of 12,214 and it has a best quartile of Q1. It has an SJR impact factor of 12,214.

Nature Reviews Clinical Oncology focuses its scope in these topics and keywords: biomarkerdriven, discovery, trials, cancer, standard, clinical, biopsy, drug, hcc, gvhddacomitinib, ...

Type: Journal

Type of Copyright:

Languages:

Open Access Policy:

Type of publications:

Publication frecuency: -

Scopus WOS
Categories: Oncology (Q1)
Price

- €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

Nature Reviews Clinical Oncology

12,214

SJR Impact factor

155

H Index

144

Total Docs (Last Year)

587

Total Docs (3 years)

7574

Total Refs

8185

Total Cites (3 years)

277

Citable Docs (3 years)

13,76

Cites/Doc (2 years)

52,60

Ref/Doc

Aims and Scope


biomarkerdriven, discovery, trials, cancer, standard, clinical, biopsy, drug, hcc, gvhddacomitinib, glioblastomanivolumab, learntearly, limit, liquid, lorlatinibfrom, lymphomahas, lymphomaliquid, gameavoiding, fits, era, biopsies, bloodtruly, breast, cancergenetics, chemoradiation, chemosensitivityrectal, combination, dlbcl, effective, elderly, end,



Best articles by citations

Cetuximab's tip to become irresistible

View more

New scoring system for melanoma accurately stratifies risk

View more

G-CSF counteracts chemotherapy toxicity in neuroblastoma

View more

Palliative primary tumour resection in mCRC - debate continues

View more

FOLFIRI - improving toxicity in first-line treatment of advanced gastric cancer

View more

FOLFOXIRI - improving outcomes of metastatic colorectal cancer

View more

Erratum: Clinical trials of human papillomavirus vaccines and beyond

View more

NK gene donor selection in AML

View more

ALL: reducing cardiomyopathy

View more

Is androgen-deprivation therapy chosen wisely?

View more

CTCs - a predictive approach for targeted cancer therapy

View more

Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery

View more
SHOW MORE ARTICLES

Gazing at the crystal ball of European radiotherapy

View more

Patients with brain metastases in early-phase trials

View more

Can less really be more in melanoma?

View more

Long-term response in high-risk CLL

View more

Treatment of aggressive lymphomas with anti-CD19 CAR T cells

View more

Is axillary lymph node clearance required in node-positive breast cancer?

View more

CONKO conquers

View more

PD-1 blockade: opening the door to attack

View more

Improving cancer detection rates

View more

Imatinib prior to allogeneic HSCT therapy improves both relapse and nonrelapse survival in patients with Ph+ALL

View more

Locoregional versus systemic therapy - robust positive data remain elusive

View more

BRAF and MEK inhibitors - good news comes in twos!

View more

Comments

No comments ... Be the first to comment!

FAQS